Cited by 2153D Printing in Biomedical ResearchMicrofluidic and Capillary Electrophoresis ApplicationsCancer Cells and Metastasis

Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment

Open access
Tsai, Hsieh-Fu, Trubelja, Alen, Shen, Amy Q., Bao, Gang·2017·Journal of The Royal Society Interface

Abstract

Cancer remains one of the leading causes of death, albeit enormous efforts to cure the disease. To overcome the major challenges in cancer therapy, we need to have a better understanding of the tumour microenvironment (TME), as well as a more effective means to screen anti-cancer drug leads; both can be achieved using advanced technologies, including the emerging tumour-on-a-chip technology. Here, we review the recent development of the tumour-on-a-chip technology, which integrates microfluidics, microfabrication, tissue engineering and biomaterials research, and offers new opportunities for building and applying functional three-dimensional in vitro human tumour models for oncology research, immunotherapy studies and drug screening. In particular, tumour-on-a-chip microdevices allow well-controlled microscopic studies of the interaction among tumour cells, immune cells and cells in the TME, of which simple tissue cultures and animal models are not amenable to do. The challenges in developing the next-generation tumour-on-a-chip technology are also discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1098/rsif.2017.0137

Cites

209 of 209 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tumor-on-chip systems are expected to increase the effective identification of new and better cancer therapies while minimizing non-specific toxicity.

    “These tumor-on-chip systems are expected to increase the effective identification of new and better cancer therapies while minimizing non-specific toxicity [13,14,15,16,17].”

    From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [14]

    The Introduction and §4.1 (pages not provided) describe tumor-on-a-chip systems as promising for drug discovery and for screening drug molecules by efficacy and safety. The paper does not specifically say they will minimize non-specific toxicity, so that part of the claim is not supported. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Tumor-on-chip models hold promise as a cost-effective and higher-throughput resource for screening anticancer drugs.

    “Tumor-on-chip models based on these organ-on-chip systems can recreate human tumor microenvironments and now hold great promise as a new resource for cost-effective and higher-throughput screening of anticancer drugs [13,14,15,16,17] and powerful enablers of precision medicine [18].”
  • Tumor-on-chip models can recreate human tumor microenvironments.

    “Tumor-on-chip models based on these organ-on-chip systems can recreate human tumor microenvironments and now hold great promise as a new resource for cost-effective and higher-throughput screening of anticancer drugs [13,14,15,16,17] and powerful enablers of precision medicine [18].”
  • Tumor-on-a-chip platforms have the ability to recreate many cardinal TME features and show great promise as a novel technology for studying the mechanisms of tumor evolution, screening anticancer drugs and cancer therapies, and enabling precision medicine.

    “Ideally, tumor-on-a-chip platforms have the ability to recreate many cardinal TME features and show great promise as a novel technology for studying the mechanisms of tumor evolution, screening anticancer drugs and cancer therapies, and enabling precision medicine14,112,117–122.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tsai, H.-F., Trubelja, A., Shen, A. Q., & Bao, G.
Affiliations
  • Okinawa Institute of Science and Technology Graduate University (JP)
  • Rice University (US)
Corresponding author
  • Shen, Amy Q.
  • Bao, Gang
Venue
Journal of The Royal Society Interface
Published
2017-06
Volume
14
Issue
131
Pages
20170137
ISSN
  • 1742-5662 (ISSN-L)
  • 1742-5689
OpenAlex
W2695955856
Cited by
214
References
209
Citations by year
2026: 13 · 2025: 13 · 2024: 26 · 2023: 26 · 2022: 25 · 2021: 18 · 2020: 28 · 2019: 44 · 2018: 20 · 2017: 1
FWCI
2.04
Type
journal article
Language
en
Open access
Locations
  • Journal of The Royal Society Interface (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
  • Okinawa Institute of Science and Technology Graduate University (Okinawa Institute of Science and Technology Graduate University) (submittedVersion, cc-by-nc-nd)
Funders
Cancer Prevention and Research Institute of Texas (RR140081)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
tumor microenvironment, anticancer drug screening, tumor growth, tumor morphology, immunotherapy, tissue engineering, biomaterials, microfabrication
MeSH terms
Humans, Models, Biological, Neoplasms, Tissue Engineering, Microfluidics, Microfluidic Analytical Techniques, Microtechnology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review